[Pneumococcal conjugate vaccine coverage in a hospital center of the Metropolis of Lille in 2008].
OBJECTIVE
To describe the vaccine coverage of Prevenar(®), follow its evolution since its universal recommendation from 2006 and search the influence of certain socio-economic factors.


METHODS
A prospective descriptive study by a questionnaire enrolled the first 250 children born after 2001 and aged more than 2 months admitted at our hospital emergency room with their health record.


RESULTS
77.11% of children from any age merged received the first dose of Prevenar(®); 89.51% of those less than 24 months versus 60.38% of those more than 24 months, p<0.0001. The follow-up by a paediatrician and the high mother educational level influenced positively the vaccination by Prevenar(®).


CONCLUSIONS
Prevenar(®) vaccine coverage evolved well since its universal recommendation achieving a 89.51% rate for the first dose. The chase of a brought closer follow-up seems important to assess the impact of this new vaccine strategy.
Helou
D
D
Clinique pédiatrique Saint-Antoine, hôpital Saint-Vincent-de-Paul, université catholique de Lille, boulevard de Belfort, 59020 Lille, France.
Moukagni-Pelzer
M
M
Hoeusler-Vassant
V
V
Huvenne
H
H
El-Kohen
R
R
Raymond
J
J
Kalach
N
N
D002648:Child; D002675:Child, Preschool; D004522:Educational Status; D004636:Emergency Service, Hospital / Q000706:statistics & numerical data; D005260:Female; D005602:France; D000069443:Heptavalent Pneumococcal Conjugate Vaccine; D006786:Hospitals, Urban / Q000706:statistics & numerical data*; D006801:Humans; D007115:Immunization Schedule; D007223:Infant; D008297:Male; D009790:Occupations; D022242:Pneumococcal Vaccines; D017410:Practice Guidelines as Topic; D011446:Prospective Studies; D012959:Socioeconomic Factors; D011795:Surveys and Questionnaires; D014504:Urban Health; D014611:Vaccination / Q000706:statistics & numerical data*
D000069443:Heptavalent Pneumococcal Conjugate Vaccine; D022242:Pneumococcal Vaccines